Brief: Egetis Receives FDA Breakthrough Therapy Designation For Tiratricol

Egetis Therapeutics AB (publ)

15/07/2025 07:08

July 15 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

EGETIS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR TIRATRICOL FOR MCT8 DEFICIENCY

Source text: ID:nMFN3m2Tc8

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))